Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) shares hit a new 52-week low during trading on Monday . The stock traded as low as $8.78 and last traded at $8.75, with a volume of 35093 shares trading hands. The stock had previously closed at $8.86.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.75.
View Our Latest Stock Analysis on FOLD
Amicus Therapeutics Price Performance
The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The business's fifty day moving average is $9.40 and its 200 day moving average is $10.19. The company has a market cap of $2.71 billion, a P/E ratio of -48.94, a PEG ratio of 1.51 and a beta of 0.69.
Institutional Investors Weigh In On Amicus Therapeutics
Several institutional investors have recently added to or reduced their stakes in the business. OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics in the third quarter worth $26,000. Virtus Fund Advisers LLC bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $29,000. Covestor Ltd increased its holdings in Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $55,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Amicus Therapeutics in the fourth quarter worth $59,000.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
